SCHEMBL4124239

SCHEMBL4124239

COc1cccc(C(=O)c2cc(Cl)ccc2-n2c(C3OCCO3)nc(Cl)c2Cl)c1OC

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 2/20 0.38
HCRTR2 O43614 2/20 0.38
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
POLB P06746 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MAPK1 P28482 1/20 0.36
GAA P10253 1/20 0.36
NPC1 O15118 1/20 0.36
LMNA P02545 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4118491 0.86 HCRTR1 (0.35) HCRTR1HCRTR2KDM4EALDH1A1NPSR1
SCHEMBL4112572 0.81 HCRTR1 (0.37) HCRTR1HCRTR2KDM4EALDH1A1NPSR1
SCHEMBL4118375 0.79 HCRTR1 (0.37) HCRTR1HCRTR2KDM4EALDH1A1NPSR1
SCHEMBL4124313 0.78 KDM4E (0.37) HCRTR1HCRTR2KDM4EALDH1A1NPSR1
SCHEMBL4124318 0.78 KDM4E (0.37) HCRTR1HCRTR2KDM4EALDH1A1NPSR1
SCHEMBL4132498 0.78 HPGD (0.37) HCRTR1HCRTR2KDM4EALDH1A1NPSR1
SCHEMBL4119680 0.75 HPGD (0.34) HCRTR1HCRTR2KDM4EALDH1A1NPSR1
SCHEMBL13775493 0.75 L3MBTL1 (0.37) HCRTR1HCRTR2KDM4EALDH1A1MAPK1
SCHEMBL4110971 0.75 KMT2A (0.33) HCRTR1HCRTR2KDM4EALDH1A1NPSR1
SCHEMBL13775802 0.75 KMT2A (0.40) HCRTR1HCRTR2KDM4EALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR HCRTR1 1006/4885HCRTR2 2126/4885KDM4E 2123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.